Consider also the patient’s general condition, the presence of other comorbidities, whether the patient can tolerate chemotherapy, and the patient’s wishes.
According to the pathological examination of steroid hormone receptor (ER or PR), HER-2 gene expression, metastasis of axillary lymph nodes, and the choice of surgical modality, clinicians will choose a comprehensive consideration based on these results. Adjuvant therapy for breast cancer with different pathological molecular staging will be based on the clinical international and domestic breast cancer diagnosis and treatment standard consensus recommendations The most appropriate adjuvant treatment option will be chosen from among the treatment options, and different options may include one or more adjuvant treatments.
Patients are advised to see a professional mammographer for a comprehensive assessment of their treatment plan and the need for chemotherapy and other adjuvant therapy.